| 书目名称 | Risk-sharing in the Pharmaceutical Industry |
| 副标题 | The Case of Out-lice |
| 编辑 | Gerrit Reepmeyer |
| 视频video | |
| 丛书名称 | Contributions to Management Science |
| 图书封面 |  |
| 描述 | The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical com |
| 出版日期 | Book 2006 |
| 关键词 | Collaboration Management; Innovation and Technology Management; Out-licensing; Pharmaceutical Industry; |
| 版次 | 1 |
| doi | https://doi.org/10.1007/3-7908-1668-X |
| isbn_softcover | 978-3-7908-1667-9 |
| isbn_ebook | 978-3-7908-1668-6Series ISSN 1431-1941 Series E-ISSN 2197-716X |
| issn_series | 1431-1941 |
| copyright | Physica-Verlag Heidelberg 2006 |
发表于 2025-3-21 18:35:31
